Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma
| العنوان: | Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma |
|---|---|
| المؤلفون: | H. Caffier, S. Krebs, A. M. Gassel, T. Müller, Jael Backe |
| المصدر: | Archives of Gynecology and Obstetrics. 259:189-195 |
| بيانات النشر: | Springer Science and Business Media LLC, 1997. |
| سنة النشر: | 1997 |
| مصطلحات موضوعية: | Adult, Pathology, medicine.medical_specialty, Time Factors, Receptor, ErbB-2, medicine.drug_class, Monoclonal antibody, Proto-Oncogene Mas, Mice, Her 2 neu, Histologic grade, Carcinoma, medicine, Animals, Humans, Statistical analysis, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, business.industry, Endometrial cancer, Antibodies, Monoclonal, Obstetrics and Gynecology, Patient survival, General Medicine, Middle Aged, Prognosis, medicine.disease, Immunohistochemistry, Survival Analysis, Endometrial Neoplasms, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Female, Neoplasm Recurrence, Local, Tumor Suppressor Protein p53, business, Follow-Up Studies |
| الوصف: | Expression of the HER-2/neu proto-oncogene product was looked for immunohistochemically in 222 endometrial carcinomas in a retrospective follow-up study. The intensity of protein expression was correlated with patient survival. Median follow-up time was 4.8 years. In 109 (49%) of 222 endometrial carcinomas there was aberrant expression of HER-2/neu. HER-2/neu-expression did not correlate with p53-expression and proliferation rate, as determined immunohistochemically by the monoclonal antibody Ki-S1. In univariate statistical analysis aberrant HER-2/neu expression was not predictive of adjusted survival (p = 0.18) and of disease-free survival (p = 0.42). In multivariate analysis HER-2/neu-expression was not found to be an independent prognosticator (p = 0.099) as compared to FIGO-stage (p = 0.0001), histologic grade (p = 0.00099) and proliferation rate (p = 0.0013). Therefore immunohistochemically detected expression of HER-2/neu seems not to be a clinical prognosticator in endometrial cancer. |
| تدمد: | 1432-0711 0932-0067 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::039e480d25251ea52f327d82bc3b93de https://doi.org/10.1007/bf02505331 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....039e480d25251ea52f327d82bc3b93de |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14320711 09320067 |
|---|